CA19-9 (Sialyl Lewis A)(121SLE) , 0.2mg / mL

CA19-9 , a carbohydrate epitope expressed on a high MW (>400 kDa) mucin glycoprotein , is a sialyl Lewisa structure which is synthesized from type 1 blood group precursor chains. It is present in individuals expressing the Lewisa and/or Lewisb blood group antigens. In normal tissues , sialyl Lewisa antigen is present in ductal epithelium of the breast , kidney , salivary gland , and sweat glands. Its expression is greatly enhanced in serum as well as in the majority of tumor cells in gastrointestinal (GI) carcinomas , including adenocarcinomas of the stomach , intestine , and pancreas. Preoperative elevated CA19-9 levels in patients with stage I pancreatic carcinoma decrease to normal values following surgery. When used serially , CA19-9 can predict recurrence of disease prior to radiographic or clinical findings. This MAb is excellent for staining of formalin-fixed , paraffin-embedded tissues._x000D_ _x000D_ This antibody is available purified with BSA/azide at 200 ug/ mL , or BSA/azide-free at 1 mg / mL.